I would like more information on FibroScan
To learn more about FibroScan and our family of products please fill out our contact form and speak with a representative!
Powered by proprietary VCTE™ and CAP™ technologies, FibroScan® can
simultaneously quantify stiffness of liver tissue and provide an approximation of
fat in the liver. With over 4,500 systems placed worldwide, the FibroScan®
examination has become a standard in many prominent liver disease guidelines,
supporting healthcare practitioners around the world.
FibroScan® is FDA cleared as an aid for the diagnosis and monitoring of adult
patients with liver disease and is supported by over 2,000 independent peer
FibroScan® is designed for simplicity and reproducibility
FibroScan® is the reference for non-invasive
assessment of liver disease across major
As your needs to quickly diagnosis and manage patients with liver disease
increase, FibroScan® systems are becoming more portable to provide greater
access for patients.
In addition to FibroScan® 502 Touch and the FibroScan® 530 Compact, we now
offer enhanced portability with FibroScan® 430 mini+, making non-invasive liver
diagnostics accessible to patients- wherever they are.
Echosens North America Inc.
950 Winter St
Waltham, MA 02451
FibroScan® refers to the family of products manufactured by Echosens™.
Echosens is the innovator in the field of non-invasive assessment of liver disease
at point of care. Our FibroScan® products have been FDA cleared as a tool to
quantitatively diagnose and monitor adult patients with liver disease, as part of an
overall assessment of liver health.
Intended Use / Indications for Use
The FibroScan® Family of Products (Models: 502 Touch, 530 Compact, and 430 Mini+) is
intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as
well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in
internal structures of the body.
FibroScan® Family of Products (Models: 502 Touch, 530 Compact, and 430 Mini+) is indicated
for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness
as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation
Parameter). The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis
and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.
Shear wave speed and stiffness may be used as an aid to clinical management of pediatric
patients with liver disease.